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Abstract
The role of rhodopsin as a structural prototype for the study of the whole superfamily of G protein-
coupled receptors (GPCRs) is reviewed in an historical perspective. Discovered at the end of the
nineteenth century, fully sequenced since the early 1980s, and with direct three-dimensional
information available since the 1990s, rhodopsin has served as a platform to gather indirect
information on the structure of the other superfamily members. Recent breakthroughs have elicited
the solution of the structures of additional receptors, namely the β1- and β2-adrenergic receptors and
the A2A adenosine receptor, now providing an opportunity to gauge the accuracy of homology
modeling and molecular docking techniques and to perfect the computational protocol. Notably, in
coordination with the solution of the structure of the A2A adenosine receptor, the first “critical
assessment of GPCR structural modeling and docking” has been organized, the results of which
highlighted that the construction of accurate models, although challenging, is certainly achievable.
The docking of the ligands and the scoring of the poses clearly emerged as the most difficult
components. A further goal in the field is certainly to derive the structure of receptors in their signaling
state, possibly in complex with agonists. These advances, coupled with the introduction of more
sophisticated modeling algorithms and the increase in computer power, raise the expectation for a
substantial boost of the robustness and accuracy of computer-aided drug discovery techniques in the
coming years.
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historical perspective
G protein-coupled receptors (GPCRs) are a large superfamily of proteins expressed on the
plasma membrane that function as receivers for extracellular chemical or physical stimuli. Due
to the vast physiological and pathophysiological implications of their signaling, GPCRs
constitute particularly appealing targets for therapeutic interventions, with their modulators
making up a large share of the current drug market.
For many years, there has been little knowledge on the structure of GPCRs. With
crystallographic information available only for rhodopsin, homology modeling was widely
applied to gather indirect information on the structure of other receptors. In this review, we
provide a historical perspective on the role of rhodopsin as a prototypical GPCR, illustrating
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the massive amount of structural information about this protein that has been used as a platform
for the study of the structure-function relationships of the whole superfamily. A schematic
timeline is shown in Figure 1. As we will discuss, the structures of three additional members
of the superfamily – namely the β1 and β2-adrenergic receptors and the A2A subtype of the
adenosine receptors – have now been solved through crystallography, providing further
insights into the three-dimensional topology of GPCRs (Figure 1). In light of these data, the
generality of the structural information derived from rhodopsin and the substantial homology
among the members of the superfamily has emerged more evident than ever, while some
elements of variability have also been highlighted. The accelerated rate of the breakthroughs
in GPCR structural studies promises the accumulation of a substantial amount of information
in the years to come, with all the obvious consequent implications for pharmaceutical discovery
and structure-based drug design.
Rhodopsin: the prototypical GPCR
Rhodopsin, a receptor activated by light photons and involved in visual signal transmission,
has been the first receptor to be analyzed from a structural point of view and it still remains
the best characterized. Although considered in many respects the prototypical GPCR,
rhodopsin has a peculiarity that distinguishes it from the great majority of the superfamily
members: the protein moiety, opsin, is covalently bound through a Schiff-base to the
chromophore, a conjugated olefin known as retinal. The light driven isomerization of the latter
is what triggers the activation of the receptor, which in turn, stimulates a guanine-nucleotide
binding protein, or G protein, specialized in the transduction of the visual signaling – transducin
(Gt) – leading to the activation of a phosphodiesterase that converts cyclic guanosine 3′,5′-
monophosphate (cGMP) to GMP.
In 1851, Heinrich Müller was the first to notice the red color of the retinal rod cells [1,2], but
the seminal work on the effect of light on rhodopsin is now considered to be represented by
papers published by Boll and Kühne in November 1876 and January 1877, respectively. Franz
Boll, then a professor of physiology in Rome, was the first to observe that the color of rhodopsin
bleaches in the light and regenerates in the dark and explicitly suggest a linkage between this
phenomenon and the act of seeing [3-5]. Although in his initial communication to the Berlin
Academy of Sciences, dating November 1876, he described the dark adapted rhodopsin as
purple-red (purpurrot), in the full-length paper of 1877 Boll explained that it is, in fact, red
and called it visual red (Sehrot). To his great disappointment, immediately after his 1876
communication, Wilhelm Kühne quickly entered the field of rhodopsin, to which he referred
as visual purple (Sehpurpur), confirming some of Boll’s findings and rectifying others. Chiefly,
in opposition to Boll’s initial hypothesis, Kühne observed that the purple color of the retina
persists after death, unless it is exposed to light [6-9]. Boll became well aware of this fact soon
after his communication, as he clarified in his1877 paper, but his initial misinterpretation had
already offered a pretext to Kühne to initiates his parallel studies, which led to numerous
publications on the subject in the following years. Boll’s work, instead, was interrupted by his
premature death in Rome on December 19, 1879. Brief commentaries on Boll’s and Kühne’s
discoveries have been translated into English by their contemporary Arthur Gamgee [10,11],
while complete translations of Boll’s 1877 and Kühne’s 1879 papers have been published on
the occasion of the 100th anniversary of their exceptional discoveries, by Ruth Hubbard and
George Wald [5,9]. In the same commemorative issue of Vision Research, Baumann and
Crescitelli provided insightful accounts of the research accomplishments and lives of Boll and
Kühne [12-14], while another tribute to Kühne’s life and accomplishments has been published
in the Archives of Ophthalmology [15].
Following evidence that vitamin A, a retinoid alcohol, is important in vision, Wald
demonstrated in 1935 that light promotes the dissociation of retinene, a carotenoid now known
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as retinal, from the colloidal component of the visual pigment. Additionally, Wald
demonstrated that vitamin A and retinene subsequently re-associate with the colloid component
to reform visual purple, thus completing the cycle of the visual process. Moreover, Wald came
to realize that “visual purple behaves as a conjugated protein in which retinene is the prosthetic
group” [16]. As summarized by Hubbard in 1958, in the following years it became clear that
rhodopsin is indeed “composed of a colorless protein, opsin, combined with the hindered 11-
cis isomer of retinene”. The latter is isomerized by light to all-trans retinene, thus converting
the dark adapted rhodopsin to lumirhodopsin and metarhodopsin, the form responsible for
visual excitation [17]. We know that metarhodopsin is composed of the meta I and meta II
states, with meta II being responsible for the transmission of the visual signal. The latter, at
first, appeared to occur through coupling to an ATP-dependent cyclic nucleotide
phosphodiesterase (PDE), as reported by Miki and coworkers in 1973 [18]. However, it was
subsequently found that the coupling of rhodopsin to the PDE is dependent on GTP, rather
than ATP. A substantial contamination of the ATP with GDP is what generated the artifact.
Furthermore, as was hypothesized by Rodbell in 1971 for the glucagon-sensitive adenylyl
cyclase [19], this PDE is not coupled directly to rhodopsin. It is a GTPase that actually links
the activation of the receptor to the stimulation of the PDE that, in turn, catalyzes the hydrolysis
of cyclic GMP to GMP [20,21]. This rhodopsin-coupled GTPase was later found by Fung and
coworkers to be a heterotrimeric protein composed of α, β, and γ subunits, and dubbed by the
authors transducin [22].
Throughout the 1950s and 1960s, evidence accumulated that rhodopsin is a structural
component of the rod outer segment membrane, and that, actually, accounts for most of its
proteic content [23]. It also became clear that retinal was covalently bound to opsin via a Schiff
base [24-26]. The first molecular details of the picture, however, did not become evident until
the 1980s, when Wand and Hargrave demonstrated that the Lys residue that serves as the
attachment site is the 53rd amino acid from the C-terminus in the bovine receptor [27]. But the
greatest advance brought by the 1980s was probably the disclosure of the complete amino acid
sequence of bovine rhodopsin, which highlighted that the receptor consists of 7 transmembrane
domains (7TMs). This milestone towards the understanding of the structure of GPCRs was
achieved independently by the laboratories of Ovchinnikov, in the former Soviet Union, and
Hargrave, in the United States [28,29]. In light of their previous finding that the C-terminus of
the receptor is exposed to the cytoplasmic surface of the disk membrane, Hargrave and
coworkers could sketch the first bi-dimensional model of rhodopsin, with the N-terminus in
the extracellular milieu followed by a serpentine sequence that spans the membrane with 7 α-
helices connected by three extracellular and three intracellular loops, leaving the C-terminus
inside the cell [29]. A 7TM structure for bacteriorhodopsin had already been observed by means
of electron microscopy [30]. However, bacteriorhodopsin is a light driven proton pump which
bears only limited similarity to rhodopsin and the superfamily of GPCRs.
The coupling of sequence analysis and biochemical experiments can provide a significant
amount of insights on the structural features of a protein. In light of the disclosure of the whole
sequence of bovine rhodopsin, it became evident that the residue identified by Wand and
Hargrave as the retinal attachment site corresponds to Lys 296 and is located in the seventh
transmembrane domain (TM7), while, subsequent experiments by Sakmar and coworkers led
to the discovery that Glu 113 in TM3 acts as the counterion for the protonated Schiff base
[31]. But over ten years elapsed from the unraveling of rhodopsin’s primary and secondary
structure to the first direct experimental insights into its three-dimensional tertiary structure,
which came in 1993, when Schertler and coworkers published a 9Å projection map of bovine
rhodopsin obtained through electron crystallography of two-dimensional crystals [32]. Soon
thereafter, Baldwin combined Schertler’s findings with sequence analysis to allocate the
individual TMs to the peaks of the projection map [33]. The resulting model, which provided
the first three-dimensional arrangement of a GPCR helical bundle, has been extensively used
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to infer structural information for other receptors as well, via sequence comparison and
homology modeling [34]. This initial structural finding in 1993 was followed by a number of
advancements achieved by the same group during the 1990s through electron cryo-microscopy,
including a low resolution structure of bovine rhodopsin [35], two projection structures of frog
rhodopsin [36], and the three-dimensional map of frog rhodopsin in 1997 [37]. With the latter,
Unger and coworkers not only solved for the first time all seven helices, but also allowed the
calculation of the approximate tilt angle of each helix.
The 1990s ended, and the new millennium started with another great milestone in GPCR
structural studies: the issue of Science published on the 4th of August, 2000 contained the
report, by Palczewski and coworkers, of the first high-resolution X-ray crystal structure of a
GPCR (PDB ID: 1F88) [38]. The structure of dark-adapted bovine rhodopsin, representing the
ground state of the receptor, had been solved with a 2.8 Å resolution, providing the first
experimentally determined three-dimensional structure of a GPCR. Palczewski’s structure
unveiled the geometry of the 7TMs as well as the intracellular and extracellular loop domains
almost in their entirety, revealing the conformation of the side-chains, and a number of
intramolecular interactions. Besides confirming the helicity of the TMs and the packing
geometry of the helical bundle predicted by Schertler’s group, Palczewski’s structure also
revealed a β-hairpin conformation for the second extracellular loop, which hovers very low
over the extracellular opening of the helical bundle, thus leaving retinal sheltered in a closed
binding pocket. This feature, as subsequent publications will reveal, is typical of rhodopsin in
all the forms crystallized up until now, but not of other GPCRs. Palczeski’s crystal structure
also confirmed the disulfide bridge that connects the extracellular side of TM3 with the second
extracellular loop, a very common element of GPCR structure that had been first proposed at
the end of the 1980s by Khorana and coworkers [39,40]. The role of this loop, especially in
the C-terminal half, in recognition of small molecule ligands of the adenosine and P2Y
nucleotide receptors has been probed [41]. Recently, evidence that this loop in rhodopsin might
form a reversible gate that opens during the activation process was obtained through solid
state 13C-NMR [42]. In particular, a coupling between movements of the second extracellular
loop and TM5 and a rearrangement in the hydrogen-bonding networks connecting this loop
with the extracellular ends of TM4, TM5 and TM6 have been detected upon the activation of
rhodopsin. On the basis of data derived from computational simulations and mutagenesis
experiments, we hypothesize that this role of the second extracellular loop might be common
to other members of the superfamily as well [43-45].
Palczewski’s original structure, as well as several refinements and different crystal forms
subsequently published (PDB IDs: 1HZX, 1LH9, 1U19, 1GZM, 2I35, 2I36, 3C9L, 3PED)
[46-51], shed light onto the topology of the dark-adapted rhodopsin, constrained in its inactive
state by the bound 11-cis-retinal (9-cis-retinal in the case of 3PED). Despite that extensive
breadth of the GPCR superfamily, these structures remained for several years the only example
of crystallized GPCRs and were extensively employed as templates for the constructions of
homology models, which provided the structural framework for the study of pharmaceutically
relevant receptors and facilitated the discovery and the development of their ligands. These
models were corroborated by a wealth of indirect experimental evidence, with mutation
techniques amply applied to validate them based on predicted interactions of specific
functionality of the ligand with amino acid residues of the receptor protein. For example,
neoceptors, in which a small molecule ligand is chemically modified in a fashion
complementary to the single amino acid mutation of a given GPCR, have been applied in this
manner to the study of adenosine receptors [52]. However, although vastly supported by the
experiments, up until recently the models could not be ultimately validated due to the lack of
a second GPCR to be used as a reference, and a question remained as to the soundness of
rhodopsin-based homology modeling. As we will discuss more amply in the next section, these
doubts were dispelled by the recent disclosures of the structures of the β-adrenergic receptors,
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and the A2A adenosine receptor. In particular, a comparison between the crystal structure of
the β2-adrenergic receptor in complex with carazolol (vide infra) with a rhodopsin-based model
of the complex – exercise not possible before then – finally confirmed the applicability of
homology modeling and molecular docking to the construction of GPCR-ligand complexes
[53].
Electron paramagnetic resonance spectroscopy (EPR) experiments conducted by Farrens and
coworkers had previously suggested that large molecular movements and rearrangements of
the transmembrane domains accompanied the activation of the receptor [54]. In particular the
authors suggested the requirement for the activation of rhodopsin of a distancing of TM3 from
TM6, as corroborated by a number of biochemical experiments [54,55]. The full extent of the
molecular changes that rhodopsin undergoes upon exposure to light remains yet to be
elucidated at an atomic level, however substantial progress in this direction has been made in
the last five years. Unlike the very unstable 3D crystals, 2D crystals of rhodopsin were found
by Schertler, Vogel and coworkers to retain their crystalline order under illumination [56]. The
analysis of these crystals through electron crystallography – which had already proven suitable
for low resolution 3D determinations with ground state rhodopsin [57] – yielded the first 3D
structure of the meta I photoactivated state of rhodopsin with a 5.5 Å resolution [58]. As
mentioned, in the photoactivation process, the meta I state follows the bathorhodopsin and
lumirhodopsin states and precedes the fully activated meta II state, which is responsible for
the activation of transducin. The experiments of Schertler’s group revealed that the formation
of meta I rhodopsin does not involve large rigid body movements. The structural changes are
instead circumscribed to the retinal binding pocket. Of note is that the electron density of
Trp265 (6.48 according to the Ballesteros and Weinstein numbering), located in proximity of
the kink of TM6, significantly deviates from the coordinates of the ground state structure,
suggesting that the formation of meta I might be accompanied by a conformational
rearrangement of this residue. Two years later, through solid-state NMR analysis of the meta
II state of rhosopsin, Crocker and coworkers confirmed the conformational change of Trp265
concurrent with the activation of the receptor [59]. This observation is consistent with the toggle
switch function attributed to aromatic residues located at this position not only for rhodopsin,
but also for several other GPCRs, including adrenergic, adenosine, and P2Y receptors (vide
infra) [60-62]. In line with Schertler’s results for meta I, when Nakamichi and Okada solved,
in 2006, the 3D crystal structures of bathorhodopsin (PDB ID: 2G87) and lumirhodopsin (PDB
ID: 2HPY) [63,64], they did not find global conformational changes of the receptor with respect
to the ground state. The two structures revealed that the bound retinal already abandons the
11-cis configuration in bathorhodpsin assuming a dihedral angle of about −155°, to undertake
an almost complete transition to the all-trans configuration and a relaxation of the polyene
chain in lumirhodopsin. The structure of lumirhodopsin also indicates a slight outward
movement of the mid segment of TM3 in proximity of the retinal pocket. This subtle shift,
however, does not yet produce any effect on the cytosolic side of the TM at this stage. Later
the same year, Paczewski and coworkers made yet another advancement toward the
determination of the structure of the activated rhodopsin with the publication of the 3D crystal
structure of a deprotonated intermediate of the photoactivation process (PDB ID: 2I37) [50].
This intermediate, although showing spectral similarities with meta II, does not present the
rigid body movements predicted by the above mentioned biophysical methods. The main
differences with the ground state are to be found in the intracellular loops, which in the
deprotonated intermediate appear significantly more disordered. As the authors clarify, the low
resolution of the structure – 4.15 Å –PRN prevents a clear determination of the side chains.
However, the predicted large rigid body movements, if present, would have been detected. A
possible explanation that can be proposed is that the intermediate trapped by Palczeski,
although close to the meta II state, has not yet undergone complete activation. This hypothesis
would signify that the predicted vast rearrangement of the TMs occurs only upon completion
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of the photoactivation process, hence leading to the conclusion that the activation of transducin
is a rather sudden event rather than a gradual one.
Thus far, the closest crystallographic representation of the light-activated rhodopsin is to be
found in the studies related to the unliganded opsin. In 2008, Ernst and coworkers crystallized
native opsin in its empty state (PDB ID: 3CAP), and revealed an overall topological similarity
with the retinal-bound rhodopsin, but with several substantial dissimilarities suggesting that
the receptor might have been trapped in an activated state [65], The noted differences included
rearrangements of TM5 and TM6, especially on their intracellular sides, breakage of the ionic
lock between TM3 and TM6, a feature that putatively constrains rhodopsin in its inactive
conformation, and disruption of an aromatic interaction between TM7 and the adjacent
cytoplasmic helix 8. Soon after, the authors published a further structure of opsin with a very
similar conformation, but this time, in complex with a synthetic peptide corresponding to the
extreme C-terminal fragment of the α subunit of transducin (PDB ID: 3DQB) [66], The latter
assumed an α-helical conformation with a C-terminal reverse turn and was found to be bound
into the cavity formed by the outward tilt of TM6 and the pairing of TM5 and TM6. This
information indeed confirmed the notion of a required substantial movement of the receptor’s
TM6 for it to activate its cognate G protein. According to the most recent double electron-
electron resonance (DEER) measurements, the outward movement of this TM has been
predicted to have an extent of about 5 Å and to be accompanied by smaller movements of TM1,
TM7, and helix 8 [67].
As mentioned, the transduction of the visual signal in mammals is mediated by a specialized
G protein named transducin. It is then reasonable to expect differences between the intracellular
side of rhodopsin and the corresponding portion of receptors selective for other G protein
subtypes. Moreover, the mechanism of activation envisioned for rhodopsin may also bear some
peculiarities dependent on its unique coupling to tranducin. However, invertebrate
phototransduction, unlike its mammalian counterpart, occurs via Gq, making these systems
appealing platforms for the study of a transduction pathway relevant for a variety of other
receptors. On this front, a recent advance in the understanding of the structure-function
relationships of GPCRs has been provided by the solution of the crystal structure of squid
rhodopsin (PDB ID: 2Z73, 2ZIY) [68,69], whose 2D crystals had been previously studied by
Schertler and coworkers [70,71]. Unlike its mammalian homologue, this receptor shows a
significant protrusion of the helical structures of TM5 and TM6 into the cytoplasm, which
might be related to the structural requirements for coupling to Gq [68,69].
The reasons for which rhodopsin has emerged as a prototypical GPCR for structural studies
and crystallographic analyses are multiple and not merely based on historical reasons. Above
all they may be attributed to two factors: the structural rigidity conferred to the receptor by the
covalently bound ligand and by the naturally high expression occurring in the rod cells of the
retinas of various animals. As mentioned, recent advances have allowed the crystallization of
the unliganded opsin without the presence of the rigidifying chromophore [65,66]. Always
using rhodopsin as a benchmark, Schertler and coworkers also addressed the second problem,
by solving the crystal structure of a recombinant rhodopsin mutant, bearing a stabilizing
disulfide bridge between the N-terminus and the third extracellular loop and heterologously
expressed in mammalian cells (PDB ID: 2J4Y, see also the alternative model 3C9M) [51,72].
In the last couple of years, the engineering of receptors with increased stability proved to be a
viable route to solve the crystal structure of GPCRs. It has already led to the determination of
the structures of the β-adrenergic receptors and the A2A adenosine receptor (vide infra), and it
is expected to yield further successes in the future.
Besides the crystallographic experiments, at the beginning of the millennium, Yeagle and
coworkers attempted obtain an experimentally-based structure for the activated rhodopsin
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through NMR spectroscopy [73,74]. Specifically, due to the difficulties inherent the analysis
of membrane bound proteins, the authors devised a clever scheme based on the division of the
sequence of the receptor into a series of overlapping peptides of which they gathered two
dimensional homonuclear 1H NMR spectra in solution. As a final step, the author
computationally assembled the whole helical bundle on the basis of the available biophysical
information, including not only the electron cryo-microscopy data gathered by Schertler and
coworkers, but also electron paramagnetic spectroscopy and data from zinc crosslinking of
histidine residues [37,54,55]. Using different sets of experimental data, the authors generated
models for both the ground state and meta II rhodopsin (PDB IDs: 1JFP and 1LN6). These
NMR-based models predicted a significant unwinding of the helices in the activated receptor,
which however has not been confirmed by any of the crystallographic evidences, generating
reasonable doubts on the robustness and reliability of this approach for the analysis of the
membrane bound portions. Solution NMR experiments, however, may instead prove useful
for the study of the soluble, generally nonconserved and often flexible, intracellular and
extracellular domains (see Tikhonova and Costanzi, Unraveling the structure of G protein-
coupled receptors through NMR, same issue of Current Pharmaceutical Design). These NMR-
derived structures could then be combined with homology models of the helical bundles to
generate hybrid experimental and computational structures, thus providing an effective way
of dealing with the lack of sequence and structural conservation of these regions that prevents
their modeling by homology. Alternatively, a more complete way to investigate the structure
of GPCRs by NMR may be provided by solid-state techniques. Preliminary data let hope for
future successes of these techniques in the analyses of whole receptors [75].
In addition to serving as a prototypical model for the study of the monomeric structure of the
receptors, rhodopsin is also the only member of the superfamily whose oligomeric arrangement
has been visualized experimentally. With a concerted effort of the research groups of Palczeski
and Engel, the multimeric arrangement of rhodopsin and opsin in native mouse disc membranes
has been directly observed by means of atomic-force microscopy (AFM) [76,77]. The low
resolution image obtained indicated that rhodopsin molecules are closely packed together,
forming dimers associated in rows of dimers that are then assembled into a paracrystalline layer
of rows. Docking of the crystal structure of bovine rhodopdin into the AFM image led to a
computational model (PDB ID: 1HZH) suggesting several intermolecular contacts that
stabilize the multimeric arrangement [78]. In particular, the weakest contact is predicted to
occur between TM1 and TM7 and to be responsible for the formation of the paracrystalline
layer, while stronger contacts between the third intracellular loop and TM2 are proposed to be
responsible for the formation of the rows of dimers. Finally, the strongest contacts, responsible
for the dimeric interface, are predicted to occur between TM4 and TM5 of one monomer and
the same TMs of another. This prediction is somewhat in contrast with an observation made
by Schertler and coworkers on the basis of their cryo-microscopy map of squid rhodopsin
[71], which had previously led the authors to the conclusion that the formation of rhodopsin
dimers would involve only TM4-TM4 contacts, mediated by a side of the TM different than
what later proposed by the AFM model. A subsequent experimentally supported model
proposed by Guo and coworkers for the dopamine D2 receptors reconciled the two hypothesis,
proposing that a rearrangement of the dimerization interface could be a critical component of
activation, with the AFM and the cryo-microscopy models bearing clues of the inactive and
active states, respectively [79]. Once again, the successive study of a variety of receptors, in
light of discoveries previously made on rhodopsin, pointed towards a generalization of the
conclusions, highlighting commonalities within the superfamily of GPCRs. Molecular
modeling and biochemical experiments, in fact, suggested a similar dimerization interface for
a variety of GPCRs, including, among others, the dopamine D2 receptor, and the A2A adenosine
receptor [79-82]. Moreover, recent evidence from a combination of bioluminescence and
fluorescence protein complementation combined with energy transfer approaches led to the
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demonstration of a higher order oligomeric arrangement also for the dopamine D2 receptor,
involving at least the association of four models [83].
The crystal structure of the β-adrenergic receptors and A2A adenosine
receptor: Rhodopsin is not alone
With the advent of molecular cloning and genome sequencing, it became evident that rhodopsin
is not a structurally and functionally unique receptor, but rather it is a member of a large
superfamily that in the human genome counts over 800 receptors [84]. Testifying to the ancient
evolutionary origins of GPCR signaling, genes encoding for these receptors have been
identified not only in mammalians and vertebrates, but also in a variety of additional genomes,
including, among others, those of plants, worms and fungi [85].
By the end of the 1970s, clear analogies had emerged between the system composed by light,
rhodopsin, G protein, and the GTP dependent phospodiesterase on one hand and, on the other
hand, those more in general composed by hormones, hormone receptors, G proteins, and
adenylate cyclase [86,87]. The first evidence of a structural platform common to the GPCR
superfamily, however, arose only in the mid to late 1980s, when the laboratories of Lefkowitz
and Strader published the cloning of the hamster β2-adrenergic receptor. These data indicated
a significant sequence similarity with bovine rhodopsin, and unveiled that also the newly cloned
receptor was endowed with a seven membrane spanning topology [88,89]. Twenty years
elapsed from this discovery to the crystallization of the human β2-adrenergic receptor, which
ultimately sealed the long postulated structural homology. The first structures to be disclosed,
in the fall of 2007, were obtained by the groups of Kobilka and Schertler, crystallizing the
receptor in a complex with carazolol – a partial inverse agonist – and the fragment antigen
binding (Fab) of a monoclonal antibody that recognizes the third intracellular loop (2R4S,
2R4R) [90,91]. Soon after, a higher resolution structure has been published by the groups of
Kobilka and Stevens (2RH1) [92,93]. This new structure, which unlike the first one that had a
defined electron density for the extracellular portion of the receptor and for the ligand, was
obtained through the generation of a fusion protein in which most of the third intracellular loop
of the receptor had been replaced with the T4-lysozyme, a well crystallizable protein. Also in
this case, these breakthroughs revealed a very good similarity in the topology of the helical
bundles of the β2-adrenergic receptor and rhodopsin, with an RMSD of 2.7 Å between the
Cα atoms of all residues in the transmembrane regions. The papers examined in great detail
similarities and differences between the two systems, including a thorough comparison of the
ligand binding pockets [92]. In this regard, the new data revealed a striking overlap between
the crystallized retinal and carazolol, but also identified one main difference: the second
extracellular loop, which in rhodopsin forms a β-strand and hovers very low over the binding
pocket, closing its access from the extracellular side, in the β2-adrenergic receptor has a
completely different topology that renders the pocket open and readily accessible by the ligands
and includes a short α-helical segment. Following the advances of 2007, two additional
structures were published in 2008. The first was another structure of the human β2-adrenergic
receptor fused with the T4-lysozyme, this time bearing a stabilizing point mutation and solved
in complex with the inverse agonist timolol, published by the group of Stevens [94]. Notably,
this structure suggested the presence of a cholesterol molecule in a specific binding pocket
located between TM2, TM3, and TM4. The second structure was published by the group of
Schertler, and referred to the turkey β1 receptor stabilized by a number of mutations and solved
in complex with the antagonist cyanopindolol [95]. In line with the significant sequence identity
(64 % [96]), the structure of the turkey β1 receptor was remarkably similar to that of the human
β2 receptor, the only major difference being the presence of an α-helical structure in the second
extracellular loop in the former, but not in the latter structure. In the fall of 2008, a fourth GPCR
structure, namely the A2A adenosine receptor in complex with the potent antagonist 4-2-[7-
amino-2-(2-furyl)-1,2,4-triazolo[1,5-a][1,3,5]triazin-5-yl-amino]ethylphenol (ZM241385),
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was solved through X-ray crystallography by the groups of Stevens and IJzerman and
confirmed once again the structural homology of the GPCR superfamily, in particular with
respect to the helical bundle [97]. The structure also confirmed the idea that the topology of
the second extracellular loop is probably unique to each particular receptor. In the case of the
A2A receptor, this domain assumes a conformation that is distinct from the one displayed by
rhodopsin or the β2-adrenergic receptor. However, as in the β2 receptor, the second extracellular
loop of the A2A receptor does not block the access to the entrance of the ligand binding pocket
from the exofacial side of the helical bundle, as it does in rhodopsin. Curiously, the putative
ionic lock between TM3 and TM6 seen in the rhodopsin structure and hypothesized to indicate
the inactive conformation of a receptor did not appear in the structures of either the β adrenergic
receptors or the A2A adenosine receptor. Additionally, the crystal structure of the A2A receptor
revealed a ligand binding mode somewhat different from that seen in rhodopsin and the β-ARs,
with ZM241385 binding in an extended conformation and perpendicular to the plane of the
membrane. Thus, besides confirming the many structural commonalities of GPCRs, the crystal
structure of the A2A receptor also highlighted that each receptor has its own peculiar
characteristics, with obvious consequences on molecular modeling and drug discovery.
Conclusions
Through this paper, we have reviewed, in a historical perspective, the role of rhodopsin as a
structural prototype for the study of the entire superfamily of GPCRs. Insightful reviews on
rhodopsin studies have been published by Palczewski and coworkers [98-100]. With such a
large superfamily of receptors and so little structural information, homology modeling and
molecular docking have been applied for years to the study of GPCR-ligand complexes, all
based on the various structures of rhodopsin as the sole template. As reviewed in an highly
informative article by Hanson and Stevens, breakthroughs in the last couple of years have
elucidated the structures of additional receptors, namely the β1- and β2-adrenergic receptors
and the A2A adenosine receptor [96]. Given the impressive amount of biochemical and
biophysical data that has been obtained for them, it was perfectly natural, as explained by
Lefkowitz and coworkers, that the β-adrenergic receptors became in 1986 the first receptors
whose structural similarity to rhodopsin was appreciated based on sequence analysis and,
twenty one years later, also became the first to join rhodopsin in the Olympic company of
crystallized GPCRs [101]. The availability of these structures in addition to those for rhodopsin,
now offer the unique opportunity of gauging the accuracy of molecular modeling techniques
and perfecting the computational protocol. Toward this purpose, a comparison of the crystal
structure of complex with carazolol in the β2-adrenergic receptor with an in silico model based
on homology to rhodopsin offered the first direct evidence of the applicability of homology
modeling and molecular docking to the generation of accurate three-dimensional structures
and the study of receptor-ligand interactions [53]. Moreover, subsequent to the crystallization
of the A2A adenosine receptor, Stevens and coworkers organized the first “critical assessment
of GPCR structural modeling and docking”, the results of which highlighted that the
construction of accurate models, although challenging, is certainly achievable [102]. The
docking of the ligands and the scoring of the poses clearly emerged as the most difficult
components. However, it is very encouraging that accurate models capturing most of the
receptor-ligand interactions have been submitted by a handful of groups participating in this
in silico binding experiment. Another insightful analysis of homology models of the adenosine
receptors in light of the new A2A crystal structure has been published by Ivanov and coworkers,
who also confirmed the usefulness of GPCR modeling, especially when supported by
experimental data, and suggested its applicability also to the study of the binding mode agonists
[103].
Considering the new pace of the field and the number of receptors currently under investigation,
it is reasonable to expect that crystal structures for additional members of the superfamily will
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be solved soon. As discussed, the structures so far elucidated are mostly related to the inactive
conformations of the receptors. Certainly, a further goal in the field is to derive the structure
of receptors in their signaling state, possibly in complex with agonists. Rhodopsin is no longer
the lone template for modeling, but will certainly keep serving the GPCR community as a
prototypical receptor and a generator of ideas to be tested on other systems. These advances,
coupled with the introduction of more sophisticated modeling algorithms and the increase in
computer power, raise the expectation for a substantial boost of the robustness and accuracy
of computer-aided drug discovery techniques in years to come.
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A schematic timeline representing some of the most significant milestones in the structural
studies of GPCRs – light gray boxes refer to rhodopsin; dark gray boxes refer to the β-
adrenergic receptors; white boxes refer to the adenosine A2A receptor.
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